Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2006

01-03-2006

Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women

Authors: Kyoung-Mu Lee, Sue Kyung Park, Nobuyuki Hamajima, Kazuo Tajima, Ji-Yeob Choi, Dong-Young Noh, Sei-Hyun Ahn, Keun-Young Yoo, Ari Hirvonen, Daehee Kang

Published in: Breast Cancer Research and Treatment | Issue 2/2006

Login to get access
Metadata
Title
Genetic polymorphisms of interleukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN) and breast cancer risk in Korean women
Authors
Kyoung-Mu Lee
Sue Kyung Park
Nobuyuki Hamajima
Kazuo Tajima
Ji-Yeob Choi
Dong-Young Noh
Sei-Hyun Ahn
Keun-Young Yoo
Ari Hirvonen
Daehee Kang
Publication date
01-03-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9079-6

Other articles of this Issue 2/2006

Breast Cancer Research and Treatment 2/2006 Go to the issue

Preclinical study

A possible regulatory role of 17β-estradiol and tamoxifen on glyoxalase I and glyoxalase II genes expression in MCF7 and BT20 human breast cancer cells

Preclinical study

High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model

Preclinical Study

EcoRI polymorphism of the metastasis-suppressor gene NME1 in Mexican patients with breast cancer

Review

From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies

OriginalPaper

Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc

Original Report

Use of raloxifene among women with a history of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits